Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT06890533 |
| Consolidated Lead Sponsor | Shanghai Haiyan Pharmaceutical Technology Co |
| Therapeutic Condition Cohort | Rare Genetic, Women's Health, and Other |
| Clinical Trial Phase | Phase III |
| Overall Recruitment Status | ACTIVE NOT RECRUITING |
| Registered Enrollment | 560 participants (ESTIMATED) |
| Registered Start Date | 2025-05-14 |
| WhyStopped Classification | Not Stopped |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| The Third Xiangya Hospital of Central South University | Changsha, China | Open Hospital Dossier -> |
| Sichuan Provincial People's Hospital | Chengdu, China | Open Hospital Dossier -> |
| The First Affiliated Hospital of Chongqing Medical University | Chongqing, China | Open Hospital Dossier -> |
| The Second Affiliated Hospital of Chongqing Medical University | Chongqing, China | Open Hospital Dossier -> |
Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.